ストックスクリーナーアプリを入手
2.84
1.79%
0.05
プレマーケット:
2.80
-0.04
-1.41%
前日終値:
$2.79
開ける：
$2.74
24時間の取引高:
496.29K
Relative Volume:
1.09
時価総額：
$134.31M
収益：
$144.98M
当期純損益:
$-104.19M
株価収益率:
-1.1998
EPS:
-2.367
ネットキャッシュフロー:
$-82.90M
1週間 パフォーマンス:
-1.05%
1か月 パフォーマンス:
-10.13%
6か月 パフォーマンス:
-10.13%
1年 パフォーマンス:
-51.54%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$2.675
$2.93
52週間の値動き範囲:
$2.15
$8.77
Quanterix Corp Stock (QTRX) Company Profile
Compare QTRX vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QTRX
Quanterix Corp
|
2.84 | 134.31M | 144.98M | -104.19M | -82.90M | -2.367 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Quanterix Corp Stock (QTRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-11 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2024-02-01 | 開始されました | Scotiabank | Sector Outperform |
| 2023-09-25 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-08 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-05-23 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-15 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2022-08-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-08-09 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-03-02 | アップグレード | Goldman | Sell → Neutral |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-06-04 | 開始されました | Goldman | Sell |
すべてを表示
Quanterix Corp (QTRX) 最新ニュース
Form 4 Quanterix Corp: Michael Francis Miller (CTO) For: 15 October By Investing.com - Investing.com South Africa
1,558 stock awards convert into shares for Quanterix (QTRX) technology chief Michael Francis Miller. - Stock Titan
Quanterix (NasdaqGM:QTRX) Stock Forecast & Analyst Predictions - Simply Wall Street
For Q3 board service, Quanterix (QTRX) grants director Donnelly 6,964 shares instead of cash. - stocktitan.net
A director converts awards into 4,224 shares at Quanterix (QTRX), bringing her holdings to 15,883 shares. - stocktitan.net
A 4,398-share grant replaces Q3 cash fees for Quanterix (QTRX) director Scott Mendel. - stocktitan.net
Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Quanterix (QTRX) awards its CCO 260K RSUs - Stock Titan
365,326 stock units go to two new employees at Quanterix. They vest over four years. - Stock Titan
Quanterix (QTRX) CTO converts RSUs, withholds shares for taxes - Stock Titan
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Global Multiplex Assays Market 2026 Edition Consumables Dominate Multiplex Assays with 68% Market Share - GlobeNewswire Inc.
Quanterix (NASDAQ: QTRX) CTO uses shares to cover exercise price or taxes - Stock Titan
Bruker Corporation Executive is Named Finance Chief at Quanterix - Medical Product Outsourcing
Quanterix (QTRX) director adds 3,955 shares via RSU vest - Stock Titan
Quest Diagnostics Executive Recruited to Quanterix’s Senior Management Team - Medical Product Outsourcing
Quanterix (QTRX) CCO files initial ownership report with no shares - Stock Titan
Quanterix (QTRX) director now holds 162,401 shares - Stock Titan
Quanterix (QTRX) CTO converts RSUs, withholds shares for taxes - Stock Titan
Quanterix (QTRX) Q2 2026 Earnings Call Transcript - The Globe and Mail
QTRX Maintains Rating by Canaccord Genuity -- Price Target Lowered to $3.00 - GuruFocus
Quanterix (NASDAQ:QTRX) Price Target Cut to $3.00 by Analysts at Canaccord Genuity Group - MarketBeat
Canaccord cuts Quanterix stock price target on weak Q2 results - Investing.com
Canaccord cuts Quanterix stock price target on weak Q2 results - Investing.com
GSA Capital Partners LLP Makes New Investment in Quanterix Corporation $QTRX - MarketBeat
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test - sharewise.com
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test - sharewise.com
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test - MarketBeat
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test - Yahoo Finance
Quanterix (NASDAQ:QTRX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Quanterix Stock Price Forecast. Should You Buy QTRX? - StockInvest.us
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Quanterix Corp (QTRX) director-linked trusts buy 99,400 shares in open market - Stock Titan
Quanterix Corp (QTRX) Stock News Today - TradingKey
Quanterix Corp (QTRX) Stock News Today - TradingKey
Quanterix Corp (QTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quanterix at canaccord growth conference: sales reset aims to lift growth - Investing.com
Quanterix (QTRX) Earnings Shake Up The Story As Fair Value Still Sits Higher - Yahoo Finance
QTRX Maintains Hold Rating -- Price Target Lowered to $3.00 by T - GuruFocus
TD Cowen Issues Pessimistic Forecast for Quanterix (NASDAQ:QTRX) Stock Price - MarketBeat
Quanterix earnings missed by $0.64, revenue fell short of estimates - Investing.com Canada
Quanterix Corp (QTRX) (Q2 2026) Earnings Call Highlights: Revenue Miss and Guidance Cut Amid Market Softness - GuruFocus
Earnings call transcript: Quanterix Q2 2026 revenue miss sends shares down 43% - Investing.com South Africa
Quanterix Corp (QTRX) (Q2 2026) Earnings Call Highlights: Revenue Miss and Guidance Cut Amid ... - Yahoo Finance
Quanterix (NASDAQ:QTRX) Drops 39% After Outlook Revision Pushes Breakeven Back to 2027 - TechStock²
Quanterix Q2 Earnings Call Highlights - MarketBeat
Quanterix Cuts 2026 Revenue Outlook as Commercial Challenges Delay Cash-Flow Break-Even - Yahoo Finance
Quanterix earnings missed by $0.64, revenue fell short of estimates - Investing.com
Earnings call transcript: Quanterix Q2 2026 revenue miss sends shares down 43% - Investing.com Nigeria
Quanterix Q2 2026 slides: revenue miss prompts guidance cut - Investing.com
Quanterix Corp (QTRX) 財務データ
収益
当期純利益
現金流量
EPS
Quanterix Corp (QTRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| DONNELLY WILLIAM P | Director |
Aug 12 '26 |
Buy |
2.75 |
27,155 |
74,676 |
27,155 |
| Meadows Benjamin | Chief Commercial Officer |
May 12 '26 |
Buy |
2.77 |
3,500 |
9,695 |
3,500 |
1.19%
3.48%
大文字化:
|
ボリューム (24 時間):